ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
AstraZeneca to sell drug rights to Covis Pharma in $371m deal
November 10, 2018AstraZeneca has agreed to divest its rights for Alvesco (ciclesonide), Omnaris and Zetonna (ciclesonide) medicines to Swiss speciality pharmaceutical firm Covis Pharma in a deal valued up to $371m. -
Deals this week: AstraZeneca, Yuhan, Bristol-Myers
November 10, 2018Covis Pharma currently markets the drugs in the US. The divestment will enable AstraZeneca to focus on the development of new and innovative drugs to fulfil the unmet needs of patients. -
AstraZeneca Sells Rights to Alvesco, Omnaris and Zetonna to Covis Pharma
November 10, 2018AstraZeneca has entered into an agreement with Covis Pharma to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated
Pharma Sources Insight January 2025
